Welcome to visit Zhongnan Medical Journal Press Series journal website!
Zhongnan Medical Journal Press Series of Journals Center for Evidence-Based and Translational Medicine of Wuhan University

The title
  • The title
  • The keywords
  • The author
Submit中文版

HomeArticlesVol 32,2022 No.4Detail

Prognostic value of circulating tumor cells in patients with non-small cell lung cancer: a Meta-analysis

Published on Aug. 25, 2022Total Views: 3593 timesTotal Downloads: 1579 timesDownloadMobile

Author: Ming-Zhen LI 1 Shao-Hua HE 1 Ying-Hui JIN 1, 2 Cheng CHEN 1 Si-Yu YAN 2 Yong-Bo WANG 2 Huan LIU 1 Zhi-Qing ZHOU 3 Han XIAO 4 Rui-Rui YANG 3 Li-Ming TAN 5

Affiliation: 1. Precision Medicine Centre, the Second People’s Hospital of Huaihua, Huaihua 418000, Hunan Province, China 2. Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 3. Department of Thoracic Oncology, the Second People’s Hospital of Huaihua, Huaihua 418000, Hunan Province, China 4. Department of Gastrointestinal Oncology, the Second People’s Hospital of Huaihua, Huaihua 418000, Hunan Province, China 5. Department of Clinical Pharmacy, the Second People’s Hospital of Huaihua, Huaihua 418000 Hunan Province, China

Keywords: Circulating tumor cell Non-small cell lung cancer Prognosis Meta-analysis

DOI: 10.12173/j.issn.1004-5511.202203006

Reference: Li MZ, He SH, Jin YH, Chen C, Yan SY, Wang YB, Liu H, Zhou ZQ, Xiao H, Yang RR, Tan LM. Prognostic value of circulating tumor cells in patients with non-small cell lung cancer: a Meta-analysis[J]. Yixue Xinzhi Zazhi, 2022, 32(4): 250-259. DOI: 10.12173/j.issn.1004-5511.202203006.[Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

Objective  To systematically evaluate the prognostic value of circulating tumor cells (CTCs) in patients with non-small cell lung cancer (NSCLC). 

Methods  We electronically searched CNIK, WanFang Data, CBM, VIP, PubMed, Web of Science, The Cochrane Library, and Embase database for literature regarding detection of baseline levels of CTCs and survival in NSCLC patients from inception to 28 September 2021. After screening for inclusion criteria, data extraction and quality assessment were performed followed by Meta-analysis using the RevMan 5.3 and Stata 15.0 software. 

Results  19 studies were included in this Meta-analysis with a total of 1,853 NSCLC patients. Meta-analysis revealed that NSCLC patients with high levels of CTCs had poorer progression-free survival (PFS) than those with low levels of CTCs [HR=2.49, 95% CI(1.50, 4.13), P=0.0004], but levels of CTCs had no significant predictive effect on overall survival (OS) [HR=1.18, 95%CI(0.70, 1.99), P=0.54]. 

Conclusions  Baseline CTCs levels have a significant predictive effect on PFS in NSCLC patients, but have no significant predictive ability on OS. This is an area which requires further study in the future.

Full-text
Please download the PDF version to read the full text: download
References

1.Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33. DOI: 10.3322/caac.21654. 

2.陈治国, 胡红玲, 陈宝钧. 外周血循环肿瘤细胞与非小细胞肺癌临床病理因素及预后的关系[J]. 实用医学杂志, 2017, 33(23): 3894-3898. [Chen ZG, Hu HL, Chen BJ. The prognostic value of peripheral circulating tumor cells in non-small cell lung cancer[J]. Journal of Practical Medicine, 2017, 33(23): 3894-3898.] DOI: 10.3969/j.issn.1006-5725.2017.23.011.

3.Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics[J]. Adv Exp Med Biol, 2016, 893: 1-19. DOI: 10.1007/978-3-319-24223-1_1. 

4.Liang H, Huang J, Wang B, et al. The role of liquid biopsy in predicting post-operative recurrence of non-small cell lung cancer[J]. J Thorac Dis, 2018, 10(Suppl 7): S838-S845. DOI: 10.21037/ jtd. 2018.04.08.

5.刘少博,黄波.基于生物信息学方法识别肺腺癌预后相关基因及预后风险模型的构建[J].中国免疫学杂志, 2021, 37(23): 2880-2892. [Liu SB, Huang B. Identification of prognostic genes and construction of prognostic risk model of lung adenocarcinoma based on bioinformatics[J]. Chinese Journal of Immunology, 2021, 37(23): 2880-2892.] DOI: 10. 3969/j.issn.1000-484X.2021.23.013.

6.茆春国,邓波.肺癌循环肿瘤细胞侵袭转移机制的研究进展[J]. 中国肺癌杂志, 2020, 23(3): 189-195. [Mao CG, Deng B. Research advances in the mechanism of invasion and metastasis of circulating tumor cells in lung cancer[J]. Chinese Journal of Lung Cancer, 2020, 23(3): 189-195.] DOI: 10.3779/j.issn.1009-3419.2020.03.09.

7.Heidrich I, Abdalla TSA, Reeh M, et al. Clinical applications of circulating tumor cells and circulating tumor DNA as a liquid biopsy marker in colorectal cancer[J]. Cancers (Basel), 2021, 13(18): 4500. DOI: 10.33 90/cancers13184500.

8.Jiang SS, Deng B, Feng YG, et al. Circulating tumor cells prior to initial treatment is an important prognostic factor of survival in non-small cell lung cancer: a meta-analysis and system review[J]. BMC Pulm Med, 2019, 19(1): 262. DOI: 10.1186/ s12890-019-1029-x.

9.Yan WT, Cui X, Chen Q, et al. Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis[J]. Sci Rep, 2017, 7: 43464. DOI: 10.1038/srep43464. 

10. 石晓欣,安建虹,黄业恩,等.循环肿瘤细胞和播散肿瘤细胞对食管癌患者预后的meta分析[J].南方医科大学学报, 2017, 37(2): 266-273. [Shi XX, An JH, Huang YE, et al. Prognostic value of circulating tumor cells and disseminated tumor cells in patients with esophageal cancer: a meta-analysis[J]. Journal of Southern Medical University, 2017, 37(2): 266-273.] DOI: 10.3969/j.issn.1673-4254.2017.02.21.

11. Salvianti F, Gelmini S, Mancini I, et al. Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study[J]. Br J Cancer, 2021, 125(1): 94-100. DOI: 10.1038/s41416-021-01399-6.

12. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9): 603-605. DOI: 10.1007/s10654-010-9491-z.

13. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis[J]. Trials, 2007, 8, 16. DOI: 10.1186/1745-6215-8-16.

14. Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker[J]. Clin Cancer Res, 2011, 17(4): 827-835. DOI: 10.1158/1078-0432.CCR-10-0445.

15. Dandachi N, Tiran V, Lindenmann J, et al. Frequency and clinical impact of preoperative circulating tumor cells in resectable non-metastatic lung adenocarcinomas[J]. Lung Cancer, 2017, 113: 152-157. DOI: 10.1016/j.lungcan. 2017.10.003.

16. Coco S, Alama A, Vanni I, et al. Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy[J]. Int J Mol Sci, 2017, 18(5): 1035. DOI: 10.3390/ijms18051035.

17. Sun Y, Chen Y, Li S, et al. NanoVelcro-captured CTC number concomitant with enhanced serum levels of MMP7 and MMP9 enables accurate prediction of metastasis and poor prognosis in patients with lung adenocarcinoma[J]. Int J Nanomedicine, 2017, 12: 6399-6412. DOI: 10.2147/ IJN.S144033.

18. Lindsay CR, Faugeroux V, Michiels S, et al. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups[J]. Ann Oncol, 2017, 28(7): 1523-1531. DOI: 10.1093/annonc/mdx156.

19. Yang B, Qin A, Zhang K, et al. Circulating tumor cells predict prognosis following tyrosine kinase inhibitor treatment in EGFR-mutant non-small cell lung cancer patients[J]. Oncol Res, 2017, 25(9): 1601-1606. DOI: 10.3727/096504017X14928634401178.

20. Zhou J, Dong F, Cui F, et al. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer[J]. Cancer Chemother Pharmacol, 2017, 79(4): 825-833. DOI: 10.1007/s00280-017-3269-x.

21. Qi Y, Wang W. Clinical significance of circulating tumor cells in squamous cell lung cancer patients[J]. Cancer Biomark, 2017, 18(2): 161-167. DOI: 10.3233/CBM-160090.

22. Zhang Z, Xiao Y, Zhao J, et al. Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer[J]. Respirology, 2016, 21(3): 519-525. DOI: 10.1111/resp.12696.

23. Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer[J]. J Clin Oncol, 2011, 29(12): 1556-1563. DOI: 10.1200/JCO.2010.28.7045.

24. Zhang F, Wu X, Zhu J, et al. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer[J]. Eur J Nucl Med Mol Imaging, 2021, 48(10): 3250-3259. DOI: 10.1007/s002 59-021-05260-z.

25. Tong B, Xu Y, Zhao J, et al. Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy[J]. Oncotarget, 2017, 8(49): 86615-86624. DOI: 10.18632/oncotarget.21255.

26. Yang B, Zheng D, Zeng Υ, et al. Circulating tumor cells predict prognosis following secondline AZD 9291 treatment in EGFR-T790M mutant non-small cell lung cancer patients[J]. J BUON, 2018, 23(4): 1077-1081. https://pubmed.ncbi.nlm.nih.gov/30358214/.

27. Tamminga M, de Wit S, Schuuring E, et al. Circulating tumor cells in lung cancer are prognostic and predictive for worse tumor response in both targeted- and chemotherapy[J]. Transl Lung Cancer Res, 2019, 8(6): 854-861. DOI: 10.21037/tlcr. 2019.11.06.

28. 李慧, 赵丹丹, 钟睿, 等. CellSearch技术检测非小细胞肺癌患者外周血中循环肿瘤细胞数并分析其与预后的相关性[J].肿瘤, 2019, 39(10): 804-812. [Li H, Zhao DD, Zhong R, et al. Number of circulating tumor cells in peripheral blood of patients with non-small cell lung cancer detected by CellSearch and its correlation with prognosis[J]. Tumor, 2019, 39(10): 804-812.] DOI: 10.3781/j.issn.1000-7431.2019.33.834.

29. 李昂, 何晓东, 沈佐君. 晚期非小细胞肺癌患者化疗前后的外周血循环肿瘤细胞计数与预后的关系[J]. 当代医学, 2020, 26(25): 126-127. [Li A, He XD, Shen ZJ. Relationship between circulating tumor cell count and prognosis in patients with advanced non-small cell lung cancer before and after chemotherapy[J]. Contemporary Medicine, 2020, 26(25): 126-127.] DOI: 10.3969/j.issn. 1009-4393.2020.25.051.

30. 刘秋阁, 刘亚楠, 王刚, 等.循环肿瘤细胞监测在晚期非小细胞肺癌疗效评价和预后评估中的作用[J]. 中国医科大学学报, 2020, 49(9): 812-817, 823. [Liu QG, Liu YN, Wang G, et al. Role of circulating tumor cell monitoring in the therapy efficacy evaluation and prognosis assessment of advanced non-small cell lung cancer[J]. Journal of China Medical University, 2020, 49(9): 812-817, 823.] DOI: 10.12007/j.issn.0258-4646.2020.09.009.

31. 杜静怡, 徐兴祥, 卞家蓉.外周血循环肿瘤细胞在晚期肺鳞癌患者免疫联合化疗疗效及预后中的价值初探[J]. 中国现代医药杂志, 2021, 23(3): 9-14. [Du JY, Xu XX, Bian JR. Preliminary study on the value of peripheral blood circulating tumor cells in the efficacy and prognosis of immunotherapy combined with chemotherapy in patients with advanced lung squamous cell carcinoma[J]. Modern Medicine Journal of China, 2021, 23(3): 9-14.] DOI: 10.3969/j.issn.1672-9463.2021.03.003.

32. 陈罗军, 李娜, 宋启斌. 循环肿瘤细胞预测非小细胞肺癌患者预后价值的Meta分析[J]. 中国肿瘤临床与康复, 2017, 24(10): 1162-1167. [Chen LJ, Li N, Song QB. Predictive value of circulating tumor cells for prognosis in NSCLC patients: a Meta-analysis[J]. Chinese Journal of Clinical Oncology and Rehabilitation, 2017, 24(10): 1162-1167.] DOI: 10.13455/j.cnki.cjcor.2017.10.03.

33. Zhang YC, Zhou Q, Wu YL. The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer[J]. J Hematol Oncol, 2017, 10(1): 167. DOI: 10:1186/s13045-017-0536-6.

34. 吴方, 焦娟, 杨家树, 等. 循环肿瘤细胞检测在肺癌中的研究进展[J]. 临床检验杂志, 2019, 37(8): 593-595. [Wu F, Jiao J, Yang JS, et al. Research progress of circulating tumor cell detection in lung cancer[J]. Chinese Journal of Clinical Laboratory Science, 2019, 37(8): 593-595.] DOI: 10.13602/j.cnki.jcls.2019.08.08.

35. Lozar T, Gersak K, Cemazar M, et al. The biology and clinical potential of circulating tumor cells[J]. Radiol Oncol, 2019, 53(2): 131-147. DOI: 10.2478/raon-2019-0024.

36. 闵梦云, 尹宜发, 赵新程, 等. 循环肿瘤细胞在肺癌中的临床研究进展[J].肿瘤学杂志, 2018, 24(1): 6-10. [Min MY, Yin YF, Zhao XC, et al. Clinical research progress on circulating tumor cells in lung cancer[J]. Journal of Chinese Oncology, 2018, 24(1): 6-10.] DOI: 10.11735/j.issn.1671-170X.2018.01.B002.

37. Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation[J]. Cell, 2012, 148(1-2): 349-361. DOI: 10.1016/j.cell.2011.11. 025.

38. Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy[J]. Cancer Discov, 2016, 6(5): 479-491. DOI: 10.1158/2159-8290.CD-15-1483.

39. Ried K, Eng P, Sali A. Screening for circulating tumour cells allows early detection of cancer and monitoring of treatment effectiveness: an observational study[J]. Asian Pac J Cancer Prev, 2017, 18(8): 2275-2285. DOI: 10.22034/APJCP.2017.18.8.2275.

Popular Papers
© 2022 - 2024 Zhongnan Medical Journal Press of Zhongnan Hospital of Wuhan University|Support: Yufu Technology
About NM | Contact us